14-day Premium Trial Subscription Try For FreeTry Free
$1.69
-0.0300 (-1.74%)
At Close: Jun 14, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:
Click to get the best stock tips daily for free!

About NervGen Pharma Corp.

NervGen Pharma . NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to resea... NGENF Profile

Golden Star

Ticker Date Change Price
LIN Jun 12 0.640% $434.17
BNDX Jun 12 0.637% $48.64
MAIN Jun 12 0.673% $49.01
EQR Jun 11 1.77% $65.55
RPM Jun 11 0.92% $110.28
FR Jun 11 1.52% $46.78
CAH Jun 11 1.20% $99.01
ESI Jun 11 11.50% $23.73
FTGC Jun 11 0.374% $24.09
FTSM Jun 11 0.0838% $59.68
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT